Suggested remit - To appraise the clinical and cost effectiveness of midostaurin within its marketing authorisation for treating advanced systemic mastocytosis
Status Proposed
Process STA 2018
ID number 1573

Project Team

Project lead Emily Richards

Email enquiries


Key events during the development of the guidance:

Date Update
17 May 2019 - 17 June 2019 Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance